Sitadapa 50/5MG Tab 10S

Tablet

Type 2 diabetes mellitus: to improve glycaemic control in adults as an adjunct to diet and exercise when dual therapy is appropriate.

Sitagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing glucose-dependent insulin release and reducing glucagon. Dapagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion and lowering blood glucose.

Oral tablet. Take exactly as prescribed, usually once daily, with or without food. Maintain adequate hydration; follow diet/exercise plan and monitor blood glucose as advised.

Genital fungal infection, urinary tract infection, increased urination, thirst, headache, nasopharyngitis, nausea, dizziness, hypoglycaemia (especially with insulin/sulfonylurea)

Not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration/low blood pressure, genital mycotic infections, UTIs and rare urosepsis/pyelonephritis with dapagliflozin; maintain hydration and seek care for fever, flank pain or burning urination. SGLT2 inhibitors may rarely cause euglycaemic ketoacidosis—seek urgent care for nausea/vomiting, abdominal pain, rapid breathing, or unusual fatigue. Sitagliptin may rarely cause pancreatitis and serious allergic reactions; stop and seek care for severe abdominal pain or rash/swelling. Use with caution in renal impairment; dose/continuation depends on eGFR—doctor monitoring required. Monitor for hypoglycaemia when used with insulin or sulfonylureas.

Insulin and sulfonylureas (increased hypoglycaemia risk), diuretics (increased dehydration/hypotension risk), digoxin (sitagliptin may increase levels), lithium (SGLT2 inhibitors may alter levels), strong UGT inducers like rifampicin/phenytoin/phenobarbital may reduce dapagliflozin exposure.

Store below 30°C in a dry place, protected from moisture and light. Keep out of reach of children.

Janumet-D 50/5 Tablet, Istavel D 50/5 Tablet, Zita-D 50/5 Tablet, Sitadapa 100/10 Tablet, Dapa-Sita 50/5 Tablet